COVID-19 patients had a trend toward elevated levels of prothrombotic biomarkers such as PAI-1 (median 4.5 vs 2.6pg/mL), plasminogen (median 101.5 vs 78% activity), and fibrinogen (median 393 vs 318mg/dL), evidence of increased clot strength (median TEG overall maximum amplitude 67.3mm vs 63.7mm, and Functional Fibrinogen maximum amplitude 26 vs 20.5mm), decreased clot breakdown (median TEG Lysis 0.1 vs 1.1%), and increased platelet aggregation in response to stimulation with ADP (median 69 vs 58 AUC units) and ristocetin (median 108 vs 59.5 AUC units). Here, PLG is linked to COVID-19.